A Children’s Oncology Group (COG) pediatric AML study (16) showed that CBFA2T3-GLIS2 fusion was cooperated with little recurrent mutations and upregulation of CD56, which was coordinated with our findings. Here, CBFA2T3 is linked to acute myeloid leukemia.